GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ondine Biomedical Inc (LSE:OBI) » Definitions » Debt-to-EBITDA

Ondine Biomedical (LSE:OBI) Debt-to-EBITDA : -0.05 (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Ondine Biomedical Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ondine Biomedical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was £0.24 Mil. Ondine Biomedical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was £0.20 Mil. Ondine Biomedical's annualized EBITDA for the quarter that ended in Jun. 2023 was £-9.03 Mil. Ondine Biomedical's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was -0.05.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Ondine Biomedical's Debt-to-EBITDA or its related term are showing as below:

LSE:OBI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.23   Med: -1.34   Max: -0.02
Current: -0.04

During the past 13 years, the highest Debt-to-EBITDA Ratio of Ondine Biomedical was -0.02. The lowest was -2.23. And the median was -1.34.

LSE:OBI's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.31 vs LSE:OBI: -0.04

Ondine Biomedical Debt-to-EBITDA Historical Data

The historical data trend for Ondine Biomedical's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ondine Biomedical Debt-to-EBITDA Chart

Ondine Biomedical Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.34 -2.23 -2.16 -0.02 -0.05

Ondine Biomedical Semi-Annual Data
Dec06 Jun07 Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.29 -0.01 -0.04 -0.04 -0.05

Competitive Comparison of Ondine Biomedical's Debt-to-EBITDA

For the Biotechnology subindustry, Ondine Biomedical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ondine Biomedical's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ondine Biomedical's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ondine Biomedical's Debt-to-EBITDA falls into.



Ondine Biomedical Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ondine Biomedical's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.217 + 0.325) / -11.391
=-0.05

Ondine Biomedical's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.239 + 0.196) / -9.032
=-0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2023) EBITDA data.


Ondine Biomedical  (LSE:OBI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Ondine Biomedical Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Ondine Biomedical's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Ondine Biomedical (LSE:OBI) Business Description

Traded in Other Exchanges
Address
1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.

Ondine Biomedical (LSE:OBI) Headlines

No Headlines